MedRx Co., Ltd (4586.T)
Tokyo · JPY · Healthcare · Drug Manufacturers - Specialty & Generic
¥49 (-2.00%) as of
Key statistics
- Market cap
- 3.24B
- EPS (TTM)
- -13.89
- Dividend yield
- 0.00%
- 52-week range
- 48.00 – 146.00
- Beta
- 0.60
- Revenue (TTM)
- 121M
- Profit margin
- 0.00%
- Volume
- 537.30k
About MedRx Co., Ltd
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Higashikagawa, Japan
- Employees
- 21
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.